Cyclo Therapeutics Inc
NASDAQ:CYTH
Cyclo Therapeutics Inc
Research & Development
Cyclo Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
Research & Development
-$16m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-78%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Research & Development
-$98m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Cyclo Therapeutics Inc
Glance View
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
See Also
What is Cyclo Therapeutics Inc's Research & Development?
Research & Development
-16m
USD
Based on the financial report for Sep 30, 2024, Cyclo Therapeutics Inc's Research & Development amounts to -16m USD.
What is Cyclo Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-78%
Over the last year, the Research & Development growth was -21%. The average annual Research & Development growth rates for Cyclo Therapeutics Inc have been -21% over the past three years , -32% over the past five years , and -78% over the past ten years .
